Alan Tan, MD, discusses the 8-year follow-up data from the CheckMate 214 trial of patients with advanced renal cell carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback